Relay Therapeutics, Inc. Stock Price, News & Analysis

Relay Therapeutics (Nasdaq: RLAY) announced management will participate in two investor fireside chats in November 2025. Guggenheim’s 2nd Annual Healthcare Innovation Conference is scheduled for Monday, November 10, 2025 at 11:00–11:25 a.m. ET. Jefferies 2025 Global Healthcare Conference is scheduled for Wednesday, November 19, 2025 at 11:30–11:55 a.m. ET (4:30–4:55 p.m. GMT).

The sessions will be webcast live and accessible via Relay Therapeutics’ investor Events page at https://ir.relaytx.com/news-events/events-presentations. An archived replay will be available for up to 30 days after each event.

Relay Therapeutics (Nasdaq: RLAY) will report third quarter 2025 financial results and corporate highlights after U.S. financial markets close on Thursday, November 6, 2025.

The company is a clinical-stage precision medicine firm combining computational and experimental technologies in drug discovery and is based in Cambridge, Mass.

Relay Therapeutics (NASDAQ:RLAY), a clinical-stage precision medicine company focused on developing therapies for cancer and genetic diseases, has announced its participation in two major investor conferences in September 2025.

Management will engage in fireside chats at the 2025 Wells Fargo Healthcare Conference on September 4 at 2:15 p.m. ET and the Morgan Stanley 23rd Annual Global Conference on September 10 at 11:30 a.m. ET. Both presentations will be available via webcast on the company's investor relations website, with replays accessible for 30 days after the events.

Relay Therapeutics (NASDAQ:RLAY) reported Q2 2025 financial results and clinical updates, highlighting progress in its cancer treatment programs. The company's lead candidate RLY-2608 demonstrated promising results in Phase 1b trials for breast cancer, showing a 10.3-month median progression-free survival and 39% objective response rate in PI3Kα-mutated, HR+/HER2- metastatic breast cancer patients.

The company has initiated its Phase 3 ReDiscover-2 trial comparing RLY-2608 + fulvestrant versus capivasertib + fulvestrant in HR+/HER2- breast cancer patients. Financial results showed a net loss of $70.4 million ($0.41 per share) and cash reserves of $656.8 million, expected to fund operations into 2029.

Relay Therapeutics (NASDAQ:RLAY), a clinical-stage precision medicine company, announced it will release its Q2 2025 financial results and corporate updates after market close on Thursday, August 7, 2025.

The company, which specializes in combining computational and experimental technologies for drug discovery, will provide details on its financial performance and business progress.

Relay Therapeutics (RLAY) has appointed Claire Mazumdar, Ph.D., to its Board of Directors effective June 9, 2025. Dr. Mazumdar brings significant experience in clinical-stage oncology and will provide guidance for the company's upcoming Phase 3 ReDiscover-2 breast cancer trial. She currently serves as the founding CEO of Bicara Therapeutics (BCAX) and previously led business development at Rheos Medicines, where she managed a global partnership with Roche Pharmaceuticals. Her background includes a role at Third Rock Ventures focusing on company formation, along with degrees from MIT (B.S. in biological engineering) and Stanford (MBA and Ph.D. in cancer biology).

Relay Therapeutics (RLAY) presented updated interim clinical data for RLY-2608, their pioneering allosteric, pan-mutant and isoform-selective PI3Kα inhibitor, at ASCO 2025. The data showed a median progression-free survival (PFS) of 10.3 months overall and 11.0 months in second-line patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer when combined with fulvestrant. With 12.5 months median follow-up, the study demonstrated a 67% clinical benefit rate and 39% confirmed objective response rate among patients with measurable disease. The drug maintained a favorable safety profile with 92% median dose intensity and mostly low-grade treatment-related adverse events. The company plans to initiate the Phase 3 ReDiscover-2 trial in mid-2025 and is advancing two front-line triplet regimens with CDK4/6 inhibitors.

Relay Therapeutics (NASDAQ: RLAY), a clinical-stage precision medicine company, has announced its participation in two major investor conferences in June 2025. The company's management will engage in fireside chats at the Jefferies Global Healthcare Conference on June 4 at 8:45 a.m. ET and the Goldman Sachs Global Healthcare Conference on June 11 at 2:40 p.m. ET. Both presentations will be accessible via live webcast through Relay's website, with recordings available for 30 days after each event.

Relay Therapeutics (NASDAQ: RLAY) reported Q1 2025 financial results and corporate updates, highlighting strategic cost reductions that extend cash runway into 2029. The company ended Q1 with $710.3 million in cash and investments. Key developments include the upcoming Phase 3 ReDiscover-2 trial initiation in mid-2025 and the launch of Phase 1 RLY-2608 vascular malformations trial in Q1. Significant cost-cutting measures implemented include an 80% reduction in research run rate spend, reducing research programs from four to one, and a workforce reduction of approximately 70 people. Q1 financial results showed revenue of $7.7 million, R&D expenses of $73.8 million, and a net loss of $77.1 million ($0.46 per share).